-
BeiGene NASDAQ:BGNE BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
Location: No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Beijing, BEIJING, China (Mainland) | Website: http://www.beigene.com/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
302.8B
Cash
2.593B
Avg Qtr Burn
-176M
Short % of Float
0.27%
Insider Ownership
19.49%
Institutional Own.
55.34%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BRUKINSA (zanubrutinib) Details Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma | Approved Update | |
BRUKINSA + obinutuzumab Details Cancer, Follicular lymphoma | Approved Quarterly sales | |
TEVIMBRA (tislelizumab) Details Esophageal Squamous Cell Carcinoma, Cancer | Approved Quarterly sales | |
Tislelizumab + chemo Details Cancer, Gastroesophageal adenocarcinomas | PDUFA Approval decision | |
TEVIMBRA (tislelizumab) Details Cancer, Esophageal Squamous Cell Carcinoma | PDUFA Approval decision | |
Sonrotoclax / BGB-11417 (Bcl-2 inhibitor) Details Waldenstrom macroglobulinemia | Phase 3 Data readout | |
Ociperlimab (Anti-TIGIT) Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
BRUKINSA + tislelizumab Details Cancer, Hepatocellular carcinoma | Phase 3 Data readout | |
Sonrotoclax / BGB-11417 (Bcl-2 inhibitor) + BRUKINSA Details Chronic lymphocytic leukemia | Phase 3 Data readout | |
Tislelizumab Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Ociperlimab (anti-TIGIT Ab) + tislelizumab Details Non-small cell lung carcinoma, Cervical cancer, Esophageal Squamous Cell Carcinoma, Small cell lung cancer, Cancer | Phase 2 Data readout | |
Sonrotoclax / BGB-11417 (Bcl-2 inhibitor) + Zanubrutinib Details Chronic lymphocytic leukemia | Phase 1/2 Data readout | |
BGB-16673 (BTK CDAC) Details Cancer, B-cell malignancies | Phase 1 Data readout | |
BGB-A445 w/ tislelizumab Details Renal cell carcinoma, Cancer, Bladder cancer, Melanoma | Phase 1 Update | |
BGB‑15025 (HPK1 inhibitor)+Tislelizumab Details Cancer, Solid tumor/s | Phase 1a Data readout |